GlycoNex Inc.
2024 Investor Conference



Mei-Chun Yang
President
myang@glyconex.com.tw

Targeting the Sweets Spots in Antigens

Using Anti-Glycan Antibodies to Overcome Protein Therapy Resistance

One type of glycan can be presented on multiple glycoproteins by nature.

Anti-glycan mAbs can target multiple membrane proteins

The multi-targeting nature of anti-glycan mAbs allows potential synergistic effects and escape from drug resistance in cancer therapy.



Pipelines

Anti-Glycan ADC



Biosimilar



Ab Bank

GlycoSH

> 50 Abs

Antibodies targeting tumor-associated carbohydrate antigens

Innovative programs of ADC-centric anti-glycan therapy

GNX1021 (ADC)

- MAb Safety confirmed in Phase I (GNX102)
- CMC & Preclinical in 2024-2025
- Clinical phase I in 2026 Q2



Anti-glycan mAbs



GNX203 (BsAb)

Selective glycan targeting with TME-enriched markers

Highly potential as a BsADC

GNX201 (Pro-Antibody)

- Next-generation anti-glycan pro-antibody
- Lead optimization in 2024
- Compatible with various applications
- Open for co-development



Pro-Ab ADC

TME: Tumor microenvironment

2023-2024 Accomplishments

- **GNX102 (First-in-Class Antibody)**
  - Phase 1 Completion in the US and TW: Excellent safety profile and good patient tolerance.
- **GNX1021 (ADC)**
  - Demonstrated preclinical efficacy in gastric cancer models
  - Good tolerability in rats and comparable to benchmark ADC
  - Manufacturing-ready
- **Denosumab Biosimilar**
  - Phase 1 completion in Japan
  - Phase 3 trial ready to launch

GNX102

Finished Phase-1 clinical trial

GNX102 mAb



GNX102 ADC

GNX102 phase1 clinical trial result

- 46 patients
- 10 kinds of tumors
- Two dosing designs
- US and Taiwan
- Excellent safety result

GNX1021 (ADC)

Scheduled to enter phase 1 clinical trial in 2026 Q2

(Taiwan, Japan)

Antibody-Drug Conjugate, ADC



One Dose of GNX1021 (ADC) can suppress the growth of gastric cancer

GNX102 單株抗體之腫瘤抑制效果(多劑量)



GNX1021 ADC 之腫瘤抑制效果(單劑量)



Strategic Focus and Timeline for 2025 and Beyond

GNX1021 development

- Preclinical Phase (Q4 2024 - Q3 2025)
  - Complete Toxicology Studies (by Q3 2025)
  - Manufacturing and CMC (by Q4 2025)
  - Data Package Preparation for IND Submission (Q4 2025)
- IND Submission (Q1 2026)
- Phase 1 Clinical Study Launch (Q2 2026)

Denosumab biosimilar (SPD8)

Finished phase-1

Scheduled to enter phase-3 in 2024 Q4

Denosumab biosimilar (SPD8)

Phase-1 results

- 110 patients
- Similar PK data
- No serious side effects
- Equivalent safety



Strategic Focus and Timeline for 2025 and Beyond

Denosumab Biosimilar

- Indication: Osteoporosis and preventing bone complications associated advanced cancer
- Phase 3 clinical trials are scheduled for initiation in Q4 2024, aimed at way for regulatory approval and commercialization by 2027.
- Plans for multi-country expansion into other Asian markets are in
- Market Potential:

  Positioned to capture significant market share in the biosimilar space where demand for affordable biologic alternatives is rising.

200L pipeline

Phase-1 drug production

- For cost and time efficiency

Antibody Manufacture Capability



抗體開發



量產細胞株開發



分析方法建立



產程開發



臨床試驗抗體製造

200 L pipeline

- Phase-1 drug production
- Complied with Japan GMP regulations

治験薬の製造管理、品質管理等に関する基準

GlycoSH: Anti-glycan Antibody Bank



- Specific to Tumor-associated glycan
- Well-characterized specificity
- Antibody sequence available
- Ready for production

Pipeline Strategy & Growth Potential

- Diversified Pipeline:
  GlycoNex's pipeline spans multiple therapeutic areas to balance risk and maximizing
  - innovative drugs *vs.* biosimilars
  - oncology and bone related diseases
- Innovative Drug Development:
  Our first-in-class and next-generation antibody programs (GNX102, GNX1021, GNX201, positioned to tap into high-value markets with unmet medical needs.
- Biosimilar Development:
  The development of Denosumab biosimilar in Japan provides a blueprint for future where biosimilars are expected to see rapid adoption.

Financial information

Publicly Traded since 2012/12 company code 4168	Unit: TWD, thousands 2024/06/30
Paid-in capital	1,086,401
Total Assets	1,416,154
Net Assets	1,156,291
Property, plant and equipment	834,339

GlycoNex Inc.

THANK YOU!